ClinicaliQ Trial Snapshot
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — Active Not Recruiting • Phase III • Cardiology / Cardiovascular • NCT06183931.
- ALXN2220 drug tested against placebo in adults with heart amyloidosis, measuring death and heart-related events.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events. Conditions: Transthyretin Amyloid Cardiomyopathy Interventions: ALXN2220, Placebo Lead Sponsor: Alexion Pharmaceuticals, Inc. Planned Enrollment: 1182 participants